APA (7th ed.) Citation

Shipa, M. R. A., Di Cicco, M., Balogh, E., Nitu, N. A., Mainuddin, M. D., Bhadauria, N., . . . Roussou, E. (2023). Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action? Modern Rheumatology, 33(4), 700. https://doi.org/10.1093/mr/roac086

Chicago Style (17th ed.) Citation

Shipa, Muhammad R. A., Maria Di Cicco, Emese Balogh, Naila A. Nitu, M. D. Mainuddin, Naveen Bhadauria, Dev Mukerjee, and Euthalia Roussou. "Drug-survival Profiling of Second-line Biologic Therapy in Rheumatoid Arthritis: Choice of Another Tumour Necrosis Factor Inhibitor or a Biologic of Different Mode of Action?" Modern Rheumatology 33, no. 4 (2023): 700. https://doi.org/10.1093/mr/roac086.

MLA (9th ed.) Citation

Shipa, Muhammad R. A., et al. "Drug-survival Profiling of Second-line Biologic Therapy in Rheumatoid Arthritis: Choice of Another Tumour Necrosis Factor Inhibitor or a Biologic of Different Mode of Action?" Modern Rheumatology, vol. 33, no. 4, 2023, p. 700, https://doi.org/10.1093/mr/roac086.